

I CLAIM:

1. The method of improving FMF control, in humans, which includes administering, on an average daily basis, between 5 and 15 milligrams of LTRA to a patient suffering from FMF.
2. The method of claim 1 wherein said LTRA is administrated orally.
3. The method of claim 2 wherein said LTRA is administrated orally in tablet form.
4. The method of claim 1 wherein about 10 milligrams of said LTRA is administrated, on a daily basis
5. The method of claim 1 wherein said humans are between 9 and 72 years old.

6. The method of claim 2 wherein said LTRA
consists of ZAFIRLUCAST tablets.

7. The method of claim 2 wherein said LTRA
consists of SINGULAIR tablets.